5013Background: An unmet need in the management of mCRPC is how to use approved AR signaling inhibitors (AR tx) and taxanes (T) to maximize survival for the individual patient. Pts with AR-V7+ CTCs (V7+) and, separately, high phenotypic CTC heterogeneity, demonstrate improved OS with T over AR Tx relative to pts with no V7+ CTCs and low CTC heterogeneity. We studied both markers in concert in relation to clinical outcomes. Methods: 191 blood samples from 161 unique pts were collected prior to initiation of AR Tx (n=128) or T (n=63). CTCs were detected and analyzed on the Epic Sciences platform, identifying 20 discrete phenotypic digital pathology cell features inclusive of AR & CK protein expression to define 15 unique CTC phenotypes present at variable frequencies in the samples studied. Heterogeneity, the diversity in the number of types of cells present, was quantified with a Shannon Index. Using the Epic nuclear V7 immunofluorecent assay, heterogeneity scores and V7 status were associated with outcome...